Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Accounts Payables (2016 - 2025)

Guided Therapeutics' Accounts Payables history spans 16 years, with the latest figure at $2.4 million for Q3 2025.

  • For Q3 2025, Accounts Payables rose 13.43% year-over-year to $2.4 million; the TTM value through Sep 2025 reached $2.4 million, up 13.43%, while the annual FY2024 figure was $2.1 million, 5.17% up from the prior year.
  • Accounts Payables for Q3 2025 was $2.4 million at Guided Therapeutics, up from $2.3 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $2.4 million in Q1 2021 and bottomed at $29000.0 in Q1 2023.
  • The 5-year median for Accounts Payables is $2.1 million (2024), against an average of $1.7 million.
  • The largest annual shift saw Accounts Payables crashed 96.7% in 2022 before it surged 6534.48% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $2.4 million in 2021, then fell by 7.45% to $2.2 million in 2022, then decreased by 8.92% to $2.0 million in 2023, then rose by 5.17% to $2.1 million in 2024, then grew by 13.75% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Accounts Payables are $2.4 million (Q3 2025), $2.3 million (Q2 2025), and $2.2 million (Q1 2025).